{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&_metadata=all&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&_page=0&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&max-ddpCreated=2019-07-17T14%3A40%3A19.187Z&min-questionFirstAnswered.=2019-06-24T16%3A44%3A04.06Z&min-answer.questionFirstAnswered.=2019-06-26T13%3A13%3A51.12Z&min-ddpModified.=2019-06-18T14%3A35%3A05.278Z&max-answer.questionFirstAnswered.=2019-07-18T15%3A57%3A32.143Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1135740", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135740/answer", "answerText" : {"_value" : "
A meeting was held by the Global Advisory Committee on Vaccine Safety (GACVS) on 5 to 6 June 2019. However, the Medicines and Healthcare products Regulatory Agency is not aware of any formal review of human papillomavirus vaccine safety published by GACVS in 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:24:58.8Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether they will place a copy of the World Health Organisation Global Advisory Committee on Vaccine Safety 2019 review of HPV vaccine safety in the Library of the House.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16833"} , {"_about" : "http://data.parliament.uk/resources/1135741", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135741/answer", "answerText" : {"_value" : "
At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine (Lariam) be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) accepted the recommendations and implemented the advice of the PRAC, which is reflected in the United Kingdom product information for mefloquine. In addition, the MHRA has since taken further action to ensure that these risks are adequately conveyed to UK prescribers and patients in the form of improved checklists for healthcare professionals and a patient alert card.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-10T15:26:45.817Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mefloquine"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the European Medicines Agency Pharmacovigilance Risk Assessment Committee\u2019s 2014 report on the toxicity of mefloquine (Larium).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16834"} , {"_about" : "http://data.parliament.uk/resources/1135742", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135742/answer", "answerText" : {"_value" : "
Tris (1-chloro-2-propyl) phosphate (TCIPP) is also known by its regulatory process name, tris (2-chloro-1-methylethyl) phosphate (TCCP).<\/p>
<\/p>
The Environment Agency worked with chemical authorities in the Republic of Ireland to initially assess the risks of TCPP in 2008. The potential environmental and human health risks of TCPP in products and other objects are currently being considered by the European Chemicals Agency (ECHA) and European Union member state scientists. Subsequently, building on a greater body of evidence, the ECHA, supported by Danish and German work are evaluating the properties of this substance and considering a legal restriction on it.<\/p>
<\/p>
Further information on this is expected soon and will help identify the chemical properties and environmental risks from TCPP in products like furniture.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4161", "label" : {"_value" : "Biography information for Lord Gardiner of Kimble"} } , "answeringMemberPrinted" : {"_value" : "Lord Gardiner of Kimble"} , "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-10T15:30:43.677Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Furniture: Fire Resistant Materials"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether they have assessed the environmental risks of disposing of polyurethane used in furniture which has been treated with tris (1-chloro-2-propyl) phosphate (TCIPP).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16835"} , {"_about" : "http://data.parliament.uk/resources/1135743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135743/answer", "answerText" : {"_value" : "
The Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment has considered the evidence on the potential effects of chlorinated and non-chlorinated phosphate flame retardants from all exposure sources, in general. The Committee is preparing a statement on phosphate-based flame retardants and the potential for neurodevelopmental toxicity. It is expected that the statement will be published in summer 2019.<\/p>
Chlorinated organophosphorous flame retardants are regulated under the European Union REACH (Restriction, Evaluation, Authorisation and Restriction of Chemicals) regime. The United Kingdom has been proactive in supporting the regulation of flame retardants through REACH. The European Chemicals Agency has announced an intention to restrict a number of chlorinated flame retardants. It is expected that the restriction proposal will be submitted in July 2019, followed by a public consultation.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:24:38.953Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mattresses: Fire Resistant Materials"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the risks to the neurological development of (1) foetuses, and (2) new-born children, of exposure to polyurethane mattresses treated with chlorinated phosphate flame retardants.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16836"} , {"_about" : "http://data.parliament.uk/resources/1135744", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135744/answer", "answerText" : {"_value" : "
Adverse events are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow card scheme and can be undertaken by a healthcare professional or the individual experiencing the adverse effect. The demographics required by the Yellow card scheme do not include the occupation of the subject, so military personnel are not uniquely identified.<\/p>
The aims of the "713/MoDREC/15" study do not include assessing whether individuals or their healthcare professional reported side effects to the MHRA or to follow-up whether any person experiencing side effects required any form of treatment, including an assessment of whether suitable treatment was available. Data collated in the study is self-reported by individuals and any symptoms reported may not necessarily be related to the anti-malarial taken.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"} } , "answeringMemberPrinted" : {"_value" : "Earl Howe"} , "dateOfAnswer" : {"_value" : "2019-07-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-08T16:39:39.247Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Malaria: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General\u2019s 2016\u201317 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16837"} , {"_about" : "http://data.parliament.uk/resources/1131898", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1131898/answer", "answerText" : {"_value" : "
The Department funds research via the National Institute for Health Research (NIHR). The NIHR does not itself classify any organisation in terms of charitable status or lobby group. The NIHR regards a charity as a specific type of voluntary organisation which must conform to the regulations set out in charity law particularly the Charities Act 2011. Charity is a legal status for an organisation, not a legal form or organisational structure.<\/p>
Any organisation which considers that it can carry out high-quality clinical, applied health or social care research is likely to be eligible for Departmental, NIHR-funded research programmes, either directly or with a partner. There are specific guidance documents setting out eligibility criteria for the NIHR\u2019s programmes which include information on partnership working, funding mechanism and contractual obligations including reporting and disclosure of conflicts of interest.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4703", "label" : {"_value" : "Biography information for Baroness Barran"} } , "answeringMemberPrinted" : {"_value" : "Baroness Barran"} , "dateOfAnswer" : {"_value" : "2019-06-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-26T13:13:51.12Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "International Life Sciences Institute"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government, following the publication of the study on the International Life Sciences Institute \"Are industry-funded charities promoting \u201cadvocacy-led studies\u201d or \u201cevidence-based science\u201d?, whether they classify the International Life Sciences Institute as an industry lobby group or a scientific health charity.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16316"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }